LASSA VIRUS-SPECIFIC NANOBODIES AND METHODS OF THEIR USE
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Jul 4, 2024
app pub date -
Apr 29, 2022
filing date -
Apr 29, 2021
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
Single-domain monoclonal antibodies that specifically bind Lassa virus glycoprotein (GPC) are described. The single-domain antibodies (“nanobodies”) were isolated from camel (VHH) and shark variable new antigen (VNAR) phage display libraries panned against a stabilized form of the GPC trimer. The GPC-specific nanobodies, and conjugates thereof, can be used for the diagnosis and treatment of a Lassa virus infection.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully